~~<i id='979B06EFE0'><strike id='979B06EFE0'><tt id='979B06EFE0'><pre id='979B06EFE0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：hotspot 2025-10-02 18:05:34 - browse：213

Adam's take main illustration — Molly Ferguson/STAT

Biotech is awash in PIPEs.

The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： No plane should take off without an EpiPen onboard

focus

knowledge

entertainment

explore

focus

PhysiciangroupsbackedbyWelsh,Carson,Anderson&Stowearelookingtoinfluencefederalmergerpolicy.Adobe

WSS

Peter Marks talks Operation Warp Speed for Rare Diseases

Amazon expands telehealth clinic nationwide

Bernie Sanders bashes nonprofit hospitals over their tax breaks

What the Wegovy shortage looks like for doctors — and for patients

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Mega Millions pot grows to $1.25 billion after no winner

hotspot

hotspot

focus

The high cost of giving birth even with insurance

Trump indictment: Who are the 'co

Heart attack and stroke risk calculators need revising

Pence says 'crackpot lawyers' told Trump what he wanted to hear

ChatGPT in medicine: STAT answers readers' burning questions

The high personal cost of affirmative action for Black doctors

In age of alternative facts, a scholarly course on calling out crap

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Medicare details structure of new drug price negotiation program

How doctors and nurses shape Google's AI

knowledge

There’s no way to know how good AI health technologies are

Trump indictment: Who are the 'co

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Adults seen as increasingly susceptible to measles

Takeaways from AdvaMed, the largest medical devices conference

Micronoma's microbiome cancer diagnostic approach under fire

knowledge

entertainment

explore

focus